The Immune Contexture and Cancer Therapy Aspects of the TIM-3 Checkpoint Pathway

The advent of immune checkpoint therapy revolutionizes the oncology field by achieving durable anti-tumor efficacy and immense clinical progress. Among checkpoints, T cell immunoglobulin mucin domain 3 (TIM-3) has been reported to express on both innate adaptive cells where it accounts for tolerance tumor aggression. It shows promising effects that are applicable in several cancer types. This review provides a broad overview main TIM-3 relative signaling pathways its regulatory role shape development positively. importance inhibitors control were also summarized according latest reports, discussing trial data inform rationale blockade.